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Aim: To evaluate postural control and central motor pathway involvement in type 2 diabetic patients.
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300 M.M. El Bardawil et al.Results: Most of the dynamic posturographic parameters were signiﬁcantly impaired in diabetic
patient group. There were signiﬁcant abnormalities in most of the parameters of the peripheral conduc-
tion studyof the patients compared to the controls.According to theTotal neuropathy score, 20patients
had peripheral neuropathy. In addition, there was signiﬁcant prolongation of the left CMCT, decreased
leftMEP amplitude and increasedMEP restingmotor threshold on both sides in the patients compared
to the control group. Dynamic posturographic parameters showed correlation withmost of the param-
eters of the peripheral conduction study and few of the MEP parameters. Logistic regression analysis
showed peripheral neuropathy as the main factor implicated in postural instability in these patients.
However, signiﬁcant correlation was found between MEP amplitude and MCT composite score in
patients without peripheral neuropathy.
Conclusion: Although type 2 diabetic patients had prolonged CMCT, decreased amplitude and
increased resting motor threshold of the MEP response, peripheral neuropathy was the main factor
implicated in postural instability. However, the central motor pathway changes documented could be
implicated as a possible cause.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Alexandria University Faculty of Medicine.1. Introduction
Postural instability is one of the complications associated with
diabetes mellitus (DM).1 Type 2 diabetic patients often exhibit
impaired balance and gait dynamics, and are at a greater risk
of falling. Many individuals who fall develop a fear of falling,
resulting in a further limitation of activity, reduced mobility
and physical ﬁtness.2
Postural sway is greater in diabetics with peripheral neu-
ropathy in both eyes open and eyes closed conditions.3 Periph-
eral neuropathy (PN) seems to be a primary factor leading to
sensory and motor deﬁcits, which often result in balance
impairments.4 However, other factors as autonomic neuropa-
thies, foot disorders, visual impairments and changes in pos-
tural coordination cannot be ruled out as additional causes
of postural impairment in these patients.1,5 In addition, several
parts of the central nervous system (CNS), which consists of
the spinal cord and the brain, take part in controlling posture.6
The automatic postural responses are the earliest functionally
effective responses that mediate a person’s active postural
movements’ control in response to external balance perturba-
tions.7 They are mediated by peripheral and central long la-
tency pathways. Posture is also guided by a mixture of
programs and sensory feedback. Calculations of these postural
programs and this feedback are made ahead of time in the
CNS and are always corrected after comparison to central
and peripheral reports about reality.8 Consequently, damage
to the CNS can interfere with the coordination of posture
and movement control, placing an individual in fear of his
or her own movements.
Central nervous system complications resulting from DM is
a problem that is gaining high attention. Diabetic neuropathy
involves not only the peripheral nervous system, but also the
central nervous system.9 Few data about the incidence of cen-
tral diabetic neuropathies are available but CNS degeneration
is a well known pathology in diabetic patients in the long
term.10 It was assumed that the damage of the CNS is mostly
caused by changes in cerebral circulation as well as metabolic
disturbances.11,12 Neuropathological and neuro-imaging tech-
niques revealed structural damage in the brain and spinal cord
tissues, demyelination, signs of micro and macro-angiopathies,
and cerebral atrophy.13–15 These changes may contribute to
postural impairment in diabetic patients. However, the effectof central motor pathway changes on posture control in these
patients has not been conﬁrmed.
Abnormalities of central efferent pathways can be mea-
sured by evoked potential studies.16 Motor evoked potentials
(MEPs) are useful as a non invasive and nearly painless inves-
tigation of propagation along corticospinal tracts controlling
limb and axial musculature.17 On the other hand, dynamic
posturography is a quantitative method for assessing upright
balance function under a variety of tasks that effectively simu-
late the conditions encountered in daily life.18
The aim of this work was to evaluate postural control and
central motor pathway involvement in type 2 diabetic patients.
2. Subjects and methods
This study included 30 type 2 diabetic patients and 15 healthy, age
and sex-matched control subjects. All the studied subjects were
chosen fulﬁlling the followingcriteria: agebetween40and65 years,
duration of diabetes mellitus discovery more than 5 years and a
normal or fully corrected visual acuity.19 Patients having any of
the followingwere excluded from the study:musculoskeletal prob-
lems that could interfere with their postural controlmechanisms,20
neurological disease other than those attributed to diabetes melli-
tus (e.g. stroke, parkinsonism, myopathy, non diabetic neuropa-
thy, etc . . . ),20 previous trauma or surgical operation involving
the back or lower limbs,20 concurrent intake of medications that
would affect balance,21 as well as the presence of contraindications
to the transcranial magnetic stimulation.22
Both groups were subjected to general clinical and full neu-
rological examinations. Glycosylated hemoglobin (HbA1c)
was measured in the patient group. In addition, the following
tests were applied to all studied subjects:
2.1. Computerized dynamic posturography (CDP)
Dynamic posturography18 was performed using the ‘‘Equitest
System’’; NeuroCom International, Inc. Portland, OR, USA.
The following tests were performed:
2.1.1. Sensory organization test (SOT)
The test consists of six experimental conditions. Each condi-
tion provided a special set of sensory inputs, while the subject
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on the center of gravity data recorded by the equipment, the
following parameters were measured through software version
4 of the equitest program.
1) The equilibrium score for each condition (C): It quanti-
ﬁes mean score of each of the six test conditions.
2) SOT composite score: reﬂects the patient’s overall per-
formance in SOT.
3) Sensory ratios: the relative differences in scores are
expressed as ratios. The four sensory ratios and their
physiologic meaning are summarized in Table 12.1.2. Motor control test (MCT)
It is designed to measure the automatic postural responses elic-
ited by translating the support surface in the horizontal direc-
tion (forward and backward translations). During these two
experimental sets, the tested subject stood quietly with eyes
opened, facing the visual surrounds, and tried to maintain
balance.
The measured parameters recorded were the response la-
tency (milliseconds), strength symmetry and response strength
(degrees/second) following mechanical translation (forward/
backward).The composite MCT latency was recorded as well.
2.2. Electrophysiological tests
Neuropack 2 electromyograph apparatus from Nihon Kohden
(Japan) was used to perform the electrophysiological studies.
The following procedures were carried out according to stan-
dardized techniques.
2.2.1. Peripheral nerve conduction study
The following peripheral nerves23,24 were studied to determine
the existence of peripheral neuropathy: A) Motor conduction
study for posterior tibial nerves with recording from abductor
hallucis muscle bilaterally, and deep peroneal nerves with
recording from extensor digitorum brevis muscle in both lower
limbs. In addition, posterior tibial minimal F wave latency was
recorded bilaterally.B) Sensory conduction study of sural nerve.
Recording electrodes used were surface electrodes, 7 mm in
diameter. Stimulation was done using bipolar stimulator.Table 1 The four sensory ratios and their physiologic
meaning.
Sensory ratio Ratio
pair
Signiﬁcance
SOM Condition 2 Patient makes poor use of
Somatosensory
ratio
Condition 1 Somatosensory reference
VIS Condition 4 Patient makes poor use of
visual
Visual ratio Condition 1 Reference
VEST Condition 5 Patient makes poor use of
vestibular
Vestibular
ratio
Condition 1 Cues, or vestibular cues
unavailable
PREF Condition
3 + 6
Patient relies on visual
cues even
Visual preference Condition 2 + 5 When they are inaccurate2.2.2. Motor evoked potentials (MEPs)
Transcranial magnetic stimulations (TMS)17,25,26 of the motor
cortex were delivered through a single pulse stimulator, Mag-
stim 200 (Magstim company, Whitland, Wales, UK), equipped
with a high power 90 mm circular coil, capable of generating
2 T maximum ﬁeld intensity.
For the left hemisphere stimulation, the coil was held with
face A of the coil visible from above (current anticlockwise)
and for stimulation of the right hemisphere, the coil was held
with face B visible from above. The coil was positioned tan-
gentially over the skull, with the center of the coil placed over
the cortex and the handle parallel to the sagittal plane. The
abductor hallucis muscle was activated if the center of the
coil was moved 4–6 cm frontally from the vertex and
2–3 cm laterally, contralateral to the side from which the
MEPs were recorded according to the international 10–20
system of international electroencephalographic electrode
placement.25,26
The abductor hallucis muscle responses were recorded with
7 mm surface disk electrodes taped in a belly/tendon mon-
tage.17 The following parameters were determined:
1. Resting motor threshold (RMT): It was determined by
applying the stimulus strength (given in percentage of the
maximum output of stimulator) increasingly in 5% incre-
ment with the target muscle (AH in lower limbs) in com-
plete relaxation until a compound muscle action potential
(CMAP) was seen. The RMT was deﬁned as the lowest
intensity that gives three reproducible responses about
50–100 lV.26
2. Motor evoked potential recording: The patient was asked to
do mild voluntary contraction of the target muscle. Stimu-
lus intensity was set at 20% above threshold for evoking
reproducible muscle responses.17 Three consecutive
responses were superimposed. The following were recorded:
i. The shortest MEP cortical latency (CL) was determined
from the ﬁrst visible deﬂection from the baseline.17
ii. Then the central motor conduction time (CMCT) was
calculated.25,26
The formula for calculation of CMCT by using F-wave
recording is:
CMCT ¼ CLðmsÞ  Peripheral latencyðPLÞðmsÞ:
PL ¼ ðMinimal F wave latencyþM wave latency 1Þ=2
where 1 ms is the estimate delay for turnaround time of the
antidromic volley at the anterior horn cell.
i. Peak to peak maximal amplitude of MEPs was
determined.17
2.3. Total neuropathy score (TNS)
It was calculated for each patient to determine peripheral
nerve function.27 Data from symptoms (sensory, motor, auto-
nomic), signs (superﬁcial and deep sensations, muscle strength
using Medical Research Council grading,28 and reﬂexes), and
nerve conduction studies (sural and peroneal nerves ampli-
tudes) were used for calculation of the score.
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Statistical analyses were performed using SPSS Statistics ver-
sion 20.
The data of the studied sample were not normally distrib-
uted. Quantitative data were described using measures of cen-
tral tendency (mean and median) and dispersion (standard
deviation, minimum and maximum). Mann–Whitney U test
was used to compare quantitative variables including periphe-
ral conduction study, MEP, and dynamic posturographic vari-
ables. Spearman’s rho correlation coefﬁcient was used to test
correlation between these variables. Readings that lie above
the third quartile (Q75) were considered to be abnormally
high, while those that lie below the ﬁrst quartile (Q25) were
considered to be abnormally low. Factor analysis was used to
construct a quantitative measure for the central changes from
the MEP parameters namely, MEP amplitude, RMT and
CMCT. Central factor was extracted to represent these MEP
variables. Logistic regression model was developed to deter-
mine the independent predictors (central factor, total neurop-
athy score) of impaired posture among diabetic patients.4. Results
None of the patients had autonomic manifestations, motor
weakness, or signs of upper motor neuron involvement.
The studied patients showed signiﬁcantly multiple SOT test
abnormalities. Low scores were observed in condition C1, C2,
C4 and C6((U= 109, p= .005), (U= 75, p= .000),
(U= 56.5, p= .001) and (U= 94, p= .042) respectively).
The SOT composite score was signiﬁcantly low (U= 69,
p= .004). Patients also had signiﬁcantly low somatosensory
(U= 155.5, p= .003) and visual ratios (U= 33, p= .000)
compared to the control group. Regarding the MCT, there
was a statistically signiﬁcant higher MCT composite score
(U= 62.5, p= .006) of patient group compared to control
group. The results also showed signiﬁcant prolongation of
the response latency for large backward perturbation of both
right (U= 95, p= .013) and left lower limbs (U= 95.7,
p= .013), right side medium backward perturbationTable 2 Comparison between patients and control groups regardin
score.
Variables Patients group n= 30
Somatosensory ratio
Median (Min–max) 0.96(0.86–1)
Mean ± SD 0.95 ± 0.04
Visual ratio
Median (Min–max) 0.8(0.69–0.92)
Mean ± SD 0.81 ± 0.07
SOT composite equilibrium score
Median (Min–max) 76(69–87)
Mean ± SD 76.76 ± 4.59
MCT composite score
Median (Min–max) 143.5(125–168)
Mean ± SD 143.13 ± 9.55
SOT= sensory organization test, MCT =motor control test, SD = sta
* Signiﬁcant at p 6 .05.(U= 84.500, p= .012), right side small forward perturbation
(U= 77, p= .01) Table 2.
No correlations were found between age, disease duration
and any of the dynamic posturographic parameters used.
Patient group showed impairment in motor and sensory
nerve conduction study of lower limbs as compared to control
group. Posterior tibial nerves of both sides showed statistically
signiﬁcant prolongation of distal latency (DL) (right
(U= 90.5, p= .028), left (U= 55, p= .001)), decrease of
compound muscle action potential (CMAP) amplitude (right
(U= 64.5, p= .003), left (U= 68, p= .004)), slowing of con-
duction velocity (CV) of the leg segment (right (U= 69.5,
p= .005), left (U= 58.5, p= .002)) and prolongation of F
wave latency (right (U= 74, p= .007), left (U= 53,
p= .001)) of the patient group compared to the control group.
Similarly, deep peroneal nerve on both sides showed statisti-
cally signiﬁcant prolongation of DL (right (U= 48,
p= .027), left (U= 48, p= .027)), decrease of CMAP ampli-
tude (right (U= 49, p= .003), left (U= 48, p= .003)) and
slowing of CV of the leg segment (right (U= 33.5, p=.006),
left (U= 39, p= .01)) of the patient group compared to the
control group. As regards sural nerve, it showed statistically
signiﬁcant slowing of conduction velocity of patients com-
pared to controls (U= 46.5, p= .002)).
According to the TNS, it was found that 20 (66.67%) pa-
tients had peripheral neuropathy, whereas 10 (33.34%) pa-
tients had no peripheral neuropathy.
On the other hand, TMS of the cerebral cortex demon-
strated statistically signiﬁcant prolongation of the right
(U= 59.5, p= .001) and left (U= 43.5, p= .001) MEP cor-
tical latency, decrease in the left MEP amplitude (U= 71,
p= .002), increase in right (U= 30.5, p= .000) and left
(U= 30.5, p= .000) MEP motor threshold as well as a signif-
icant left CMCT (U= 110, p= .05) delay in patient group
compared to control group. Table 3
Delayed CMCT was demonstrated in 12 (40%) and 19
(63.33%) patients on right and left sides, respectively.
Neither MEP parameters nor TNS was correlated with age.
Cortical latency was positively correlated with disease duration
(r= 0.44, p= .015) and with the TNS (r= .376, p= .04).
There was positive correlation between glycosylatedg the sensory ratios, SOT composite score and MCT composite
Control group n= 15 Mann whitney U (p-value)
0.98(0.96–1) 155.5*
0.98 ± 0.02 (.003)
0.9(0.82–0.96) 33*
0.9 ± 0.04 (.000)
81(77–87) 69*
81.03 ± 2.93 (.004)
135(124–143) 62.5*
134.20 ± 6.8 (.006)
ndard deviation, Min = minimum, Max = maximum.
Table 3 Comparison between patients and controls regarding motor evoked potential parameters.
Variables Patients group n= 30 Control group n= 15 Mann Whitney U (p-value)
Rt resting motor threshold (%)
Median (Min–max) 80(60–100) 60(40–80) 30.5*
Mean ± SD 77 ± 6 55 ± 14 (.000)
Rt motor evoked potential
 Cortical Latency (ms)
Median (Min–max) 41.8(36.6–52.2) 37.7(36.6–40.4) 59.5*
Mean ± SD 42.24 ± 4.8 37.97 ± 1.14 (.001)
 Amplitude (mV)
Median (Min–max) 0.93(0.09–1.7) 1.99(0.9–5.37) 122.5
Mean ± SD 0.87 ± 0.55 2.32 ± 1.99 (.109)
 CMCT (ms)
Median (Min–max) 14.13(8.1–19.85) 12.85(10.75–15.35) 137.5
Mean ± SD 14.42 ± 2.79 13.27 ± 1.44 (.237)
Lt Resting motor threshold (%)
Median (Min–max) 80(60–100) 50(40–80) 20*
Mean ± SD 78 ± 6 48 ± 15 (.000)
Lt Motor evoked potential
 Cortical latency (ms)
Median (Min–max) 43.6(36.2–61.8) 38.5(34.8–41.6) 43.5*
Mean ± SD 44.11 ± 5.45 37.85 ± 2.26 (.000)
 Amplitude (mV)
Median (Min–max) 0.55(0.13–3.5) 1.71(0.14–7.17) 71*
Mean ± SD 0.74 ± 0.67 2.58 ± 2.4 (.002)
 CMCT (ms)
Median (Min–max) 16.1(6.1–29.05) 12.8(10.35–17.95) 110*
Mean ± SD 15.59 ± 4.42 13.16 ± 2.09 (.05)
n= number, rt = right, lt = left, ms = millisecond, mV=milliVolt, CMCT= central motor conduction time, Max = maximum,
Min = minimum, %= percentage, SD= standard deviation.
* Signiﬁcant at p 6 0.05.
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p= .042) and CMCT (r= .552, p= .002).
Table 4 shows the statistical correlation of dynamic postu-
rographic variables with the electrophysiologic variables in pa-
tient group. There was statistically signiﬁcant correlation
between the MCT composite score and posterior tibial nerve
DL (r= .410, p= .009), CV (r= .450, p= .004), and
CMAP amplitude (r= .359, p= .029), as well as with the
deep peroneal CV (r= .483, p= .003), and CMAP ampli-
tude (r= .396, p= .019). In addition, the MCT composite
score was positively correlated with the TNS (r= .498,
p= .001) as well as negatively correlated with the MEP ampli-
tude (r= .363, p= .021).
Regarding the SOT composite score, it was signiﬁcantly
correlated with the posterior tibial CMAP amplitude
(r= .346, p= .048) and F wave minimal latency
(r= .451, p= .008). In addition, it was positively correlated
with the MEP cortical latency (r= .361, p= .0329).
There was statistically signiﬁcant correlation between the
somatosensory ratio and posterior tibial nerve DL
(r= .539, p= .000), CV (r= .354,p= .003), CMAP ampli-
tude (r= 454, p= .021), deep peroneal nerve CMAP ampli-
tude (r= .340, p= .04), TNS (r= .372, p= .043), as well
as amplitude of the MEP response (r= .328, p= .034) and
cortical latency (r= .330, p= .033). Regarding the visual
ratio, it was correlated with posterior tibial nerve DL
(r= .382, p= .028), NCV (r= .346, p= .048), CMAPamplitude (r= .354, p= .043), F wave minimal latency
(r= .449, p= .009), as well as cortical latency of the MEP
response (r= .371, p= .034). No statistically signiﬁcant
correlations were found between the vestibular or visual pref-
erence ratio and any of the electrophysiologic variables.
Every subject with at least one altered posturographic
parameter was considered to have impaired postural control.
After recording every subject with impaired posture, logistic
regression analysis was applied.
The logistic regression model explains only 45.9% of the
occurrence of postural impairment. Only the peripheral neu-
ropathy is signiﬁcantly contributing to the model (p= .016)
(Adjusted OR= 1.167, 95% CI = 1.030, 1.323). Accordingly,
only peripheral neuropathy appeared to signiﬁcantly contrib-
ute to the postural impairment in the patient group. Whereas
peripheral neuropathy explains only 45.9% of the occurrence
of postural impairment, it was found that the central factor
was not an independent predictor of postural impairment
(p> .05, i.e. p= 0.78).
As regards correlation of TNS and central factor with pos-
turographic parameters TNS was positively correlated with
somatosensory ratio (r= .322, p= .031) and MCT composite
score (r= .498, 0.001). On the other hand, Central factor was
positively correlated only with MCT composite score
(r= .314, 0.048). Table 5
Regarding the 10 patients having no PN, correlation of the
MEP parameters with dynamic posturographic variables
Table 4 Correlation of dynamic posturographic variables with selected electrophysiologic variables and TNS in patient group.
Variables MCT composite score SOT composite score Somatosensory ratio Visual ratio
r p r p r p r p
Posterior tibial nerve
 Latency (mses) .410** .009 .361 .089 .539** .000 .458** .007
 CV (m/sec) .450** .004 .270 128 .354** .003 .432* .012
 CMAP amplitude (mV) .359* .029 .346* .048 .454* .021 .382* .028
 F wave latency .498 .001 .451** .008 .274 .079 .449** .009
Deep peroneal nerve
 Latency (mses) .268 .119 .301 .675 .282 .091 .116 .557
 CV (m/sec) .483** .003 .190 .334 .295 .077 .390* .040
 CMAP amplitude (mV) .396* .019 .115 .560 .340* .04 .098 .621
Resting motor threshold(%) .292 .067 .157 .383 .158 .317 .343 .051
Motor evoked potential
 Cortical latency (ms) .308 .053 .399* .022 .330* .033 .371* .034
 Amplitude (mV) .363* .021 .328 .063 .328* .034 .097 593
 CMCT .086 .598 .034 .849 .254 .105 .124 .492
Total neuropathy score .498** .001 .103 .655 .372* .043 .115 .620
msec = millisecond, SOT= Sensory organization test, m/sec = meter per second, MCT= motor control test, mV =milliVolt, CV = Con-
duction velocity, CMAP= Compound muscle action potential, CMCT= central motor conduction time, %= percentage, r= Spearman’s
rho correlation coefﬁcient.
* Signiﬁcant at p 6 .05 level.
** Signiﬁcant at p 6 .01 level.
Table 5 Correlation matrix between central factor, total neuropathy score and posturographic parameters.
Variable Central factor Total neuropathy score
r p r p
SOT composite score .076 .673 .278 .100
Somatosensory ratio .067 .675 .322* .031
Visual ratio .253 .156 .319 .058
Vestibular ratio .060 .739 .114 .507
Visual preference ratio .101 .575 .070 .686
MCT composite score .314* .048 .498** .001
MCT=motor control test, SOT = Sensory organization test, r= Spearman’s rho correlation coefﬁcient,
* Signiﬁcant at p 6 .05 level (2-tailed).
** Signiﬁcant at p 6 .01 level.
304 M.M. El Bardawil et al.showed signiﬁcant negative correlation between amplitude of
the MEP response and MCT composite score (r= .658,
p= .038) Table 6.
5. Discussion
It is well known that gait characteristics and balance are al-
tered in diabetic patients.4 Regarding the postural control of
the diabetic patients in the present study, SOT analysis indi-
cates an overall decrease in patients’ performance and sensory
function with speciﬁc affection of somatosensory and visual
system.29 This contributes signiﬁcantly and negatively to their
balance. Low condition 2 score and somatosensory ratio of pa-
tient group relative to the controls points to somatosensory
impairment.29 On the other hand, low condition 4 score and
visual ratio of the patient group points to visual impairment
that could be at the subclinical level. Many visual problems
can appear soon in diabetics, even sooner than neuropathy.30
A signiﬁcant deterioration in color vision and/or contrastsensitivity in diabetic patients without retinopathy compared
to non diabetic controls has been documented.31 Lack of sig-
niﬁcant difference between patient and control groups regard-
ing condition 3 and visual preference ratio signiﬁes that low
condition 6 scores are probably due to the difﬁculty in using
the visual information by the patient group.18
MCT automatic response latencies showed signiﬁcant pro-
longation in the patient group compared to the control group.
The presence of prolonged MCT response latency translations
as well as MCT composite score with normal MCT response
strength and absence of asymmetry in weight bearing indicate
a pathological deﬁcit within the long loop pathway mediating
automatic postural responses. The latter includes sensory and
motor peripheral nerves, the ascending and descending motor
pathways, and the motor regions of the brain and cerebral cor-
tex. Besides, prolonged MCT response latency results for med-
ium and large translations limited to one movement direction
(i.e. backward translation) suggest that the lesion is more likely
to be in the efferent branch of the long loop pathway.18
Table 6 Correlation of the motor evoked potential parameters of the 10 patients without PN with dynamic posturographic variables.
Variable Cortical latency (msec) Amplitude (mV) Resting motor threshold (%) CMCT (msec)
r p r p r p r p
SOT composite score .600 .116 .123 .772 .089 .853 .494 .214
Somatosensory ratio .268 .453 .357 .312 .529 .116 .463 .178
Visual ratio .543 .164 .145 .731 .103 .808 .506 .201
Vestibular ratio .148 .726 .355 .388 .048 .909 .427 .292
Visual preference ratio .147 .728 .172 .684 .596 .596 .346 .402
MCT composite score .019 .959 .658* .038 .470 .171 .297 .404
msec = millisecond, mV=milliVolt, SOT= sensory organization test, MCT= motor control test, CMCT= central motor conduction time.
* Signiﬁcant at p 6 .05, r= Spearman’s rho correlation coefﬁcient.
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the any of the dynamic posturographic variables. This was in
agreement with several authors32,33 who reported a lack of this
association. HbA1c can be interpreted as an average of the
blood glucose present over the past 3–4 months.34 It might
not reﬂect cumulative hazardous effects of diabetes mellitus
on postural control. This might explain the lack of this associ-
ation. However, larger sample size might demonstrate such
relation.
On the other hand, the consequences of chronic diabetes
mellitus in the CNS are less known than diabetic PN and auto-
nomic nervous system neuropathy.10 In diabetic patient group,
prolonged CMCT could be due to central motor neuropathy.
In addition, MEP amplitude was signiﬁcantly lower than that
of the control group. Taken together, the combined low ampli-
tude and prolonged CMCT of the MEP response suggests the
presence of central motor pathway affection, whose underlying
pathology may be combined demyelination and loss of axons or
neurons of the corticospinal tract.26,35,36 This indicates the
presence of subclinical central motor changes in those patients
as documented in many studies.37–40 In this context, the present
results also revealed increased MEP resting motor threshold
(RMS) on both sides in the studied patients reﬂecting decreased
excitability of the cortical and/or spinal motor neurons.35,37,38
In the present work, age and disease duration were not cor-
related with most of the studied variables of the MEPs re-
sponse and the dynamic posturography indicating that
abnormalities of central motor pathway and postural control
might be related to other disease variables rather than these.
In support of this view, cortical latency of the MEP response
and CMCT were positively correlated with glycosylated hemo-
globin. This indicates that central affection might be related to
the degree of glycemic control which agrees with many
authors37–40 who reported that CMCT delay in diabetic pa-
tients was related to the degree of metabolic control. Our re-
sults were in agreement with those of Sabry et al.10 who
found no correlation between CMCT delay and patients’ age
or disease duration. However, contrary to the present ﬁndings,
the studies conducted by Imam et al.38 demonstrated a statis-
tically signiﬁcant positive correlation between CMCT delay
and both the age of type 2 diabetic patients and the duration
of diabetes. The alteration of the central motor pathways sup-
ports the hypothesis that the central nervous system involve-
ment in DM represents a process that is possibly partially
dependent on degree of metabolic control as well as other fac-
tors. These factors were suggested to include enhanced ﬂux
through the polyol pathway, accelerated formation ofadvanced glycation end products, oxidative damage and
microvascular changes and alterations of the cerebral vascular
system.41,42
Most of the posturographic parameters correlated well with
the majority of the peripheral conduction study parameters
(supported by logistic regression analysis) whereas the MEPs
study showed few correlations with these posturographic
parameters. Therefore, it seems that PN is the main cause of
the postural instability in the studied patients. In agreement
with this result, Di Nardo et al.21 suggested that the main
cause of postural instability in diabetes was PN rather than le-
sions of the spinal cord. Similarly, Emam et al.43 suggested
that PN is the main cause of postural impairment in diabetic
patients. The mechanisms by which PN leads to postural insta-
bility are complex including the lack of accurate propriocep-
tive feedback from the lower limbs,44 impairment of ankle
strength, balance recovery and walking stability in diabetics.43
Despite numerous studies on different aspects of CNS
affection in diabetic patients, yet little work was reported on
its relationship to postural impairment in such patients. In
the current study, it was found that PN, assessed by total neu-
ropathy score, has the primary inﬂuence on the postural con-
trol. However, the presence of signiﬁcant negative correlation
between the amplitude of the MEP response and the MCT
composite score in the diabetic patients without peripheral
neuropathy (decreased MEP amplitude is correlated with in-
creased MCT composite score and vice versa) indicates that
central motor changes could be a possible cause of postural
instability in these patients together with visual and somato-
sensory dysfunction (as proved by SOT results).
It can be concluded that alteration in the peripheral nerve
function was the main factor implicated in postural instability
in the studied patients. However, the central motor pathway
changes documented could be implicated as a possible cause.References
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